S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.

Property Value
dbo:abstract
  • S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-06-16 01:17:12Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 22287450 (xsd:integer)
dbo:wikiPageLength
  • 3241 (xsd:integer)
dbo:wikiPageModified
  • 2019-06-12 17:45:23Z (xsd:date)
dbo:wikiPageOutDegree
  • 18 (xsd:integer)
dbo:wikiPageRevisionID
  • 901555045 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment. (en)
rdfs:label
  • S-23 (drug) (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is foaf:primaryTopic of